Header

UZH-Logo

Maintenance Infos

Treatment of severe cold contact urticaria with omalizumab: case reports


Brodská, Petra; Schmid-Grendelmeier, Peter (2012). Treatment of severe cold contact urticaria with omalizumab: case reports. Case Reports in Dermatology, 4(3):275-280.

Abstract

We report 2 patients with cold urticaria with different response to treatment with omalizumab (Xolair(®)). Cold contact urticaria (CCU) is a common subtype of physical urticaria. It is characterized by the development of wheal and/or angioedema within minutes after cold contact. Clinical manifestation of CCU can range from mild, localized whealing to life-threatening anaphylactic shock reactions. Omalizumab has been described to be useful in cases of chronic urticaria and may be an interesting option for treatment of CCU. We describe one patient with significant and long-lasting improvement of symptoms and one without any improvement after anti-immunoglobulin E therapy. In our case reports, we want to highlight that there is still a small group of patients without benefit from omalizumab treatment. It is necessary to identify this minor subgroup of patients where omalizumab does not represent an effective treatment possibility.

Abstract

We report 2 patients with cold urticaria with different response to treatment with omalizumab (Xolair(®)). Cold contact urticaria (CCU) is a common subtype of physical urticaria. It is characterized by the development of wheal and/or angioedema within minutes after cold contact. Clinical manifestation of CCU can range from mild, localized whealing to life-threatening anaphylactic shock reactions. Omalizumab has been described to be useful in cases of chronic urticaria and may be an interesting option for treatment of CCU. We describe one patient with significant and long-lasting improvement of symptoms and one without any improvement after anti-immunoglobulin E therapy. In our case reports, we want to highlight that there is still a small group of patients without benefit from omalizumab treatment. It is necessary to identify this minor subgroup of patients where omalizumab does not represent an effective treatment possibility.

Statistics

Citations

Dimensions.ai Metrics

29 citations in Scopus®
27 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

88 downloads since deposited on 29 Jan 2013
9 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Omalizumab, Physical urticaria, Anti-immunoglobulin E, Cold contact urticaria
Language:English
Date:2012
Deposited On:29 Jan 2013 12:14
Last Modified:17 Feb 2018 00:48
Publisher:Karger
ISSN:1662-6567
OA Status:Gold
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1159/000346284

Download

Download PDF  'Treatment of severe cold contact urticaria with omalizumab: case reports'.
Preview
Content: Published Version
Language: English
Filetype: PDF
Size: 621kB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)